26 May 2016 - The EMA has published an EPAR for selexipag (Uptravi).

The European Commission approved Uptravi on 12 May 2016 for the long-term treatment of pulmonary arterial hypertension in adult patients with WHO functional class II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase type 5 inhibitor, or as monotherapy in patients who are not candidates for these therapies.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003774/human_med_001970.jsp&mid=WC0b01ac058001d124